Niemann-Pick Disease, Type C Clinical Trial
— RAINBOWOfficial title:
Randomized, Double Blind, Placebo Controlled, Multicenter, 12 Weeks Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
Verified date | February 2024 |
Source | Azafaros A.G. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase 2 is a randomized, double-blind, placebo controlled, 12 weeks study with daily oral administration of AZ-3102 aiming to evaluate the safety and pharmacokinetic (PK) profile in GM2 Gangliosidosis and Niemann-Pick type C disease (NP-C) patients. If approved by the country health authorities, a double-blind extension period will be proposed to the patients who complete the 12-week study.
Status | Active, not recruiting |
Enrollment | 13 |
Est. completion date | December 2024 |
Est. primary completion date | March 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 20 Years |
Eligibility | Inclusion Criteria: - Male and female patients aged between 12-20 years old at informed consent signature. - GM2 patients : Genetically and biochemically confirmed diagnosis of Tay-Sachs or Sandhoff disease. - NP-C patients : Genetically confirmed diagnosis of NP-C. - NP-C patients : Miglustat-naïve patients unwilling or unable to take miglustat, OR, patients who have discontinued miglustat because of confirmed safety/tolerability issues. Miglustat must have been discontinued at least 1 month prior to Baseline visit. - Total SARA score = 1 at Baseline. - A male participant with a female partner of childbearing potential is eligible if he agrees to follow the contraceptive guidance. - If a female participant is a WOCBP and is having a male partner, she must agree to follow the contraceptive guidance. - Willing and able to complete protocol assessments. - Parent and/or legal guardian is able to read, understand, and sign the informed consent. Where appropriate, assent will also be sought for patients who have not reached the age of majority or who are not able to sign the consent form. Exclusion Criteria: - Any abnormal conditions at baseline visit which, in the opinion of the PI; could interfere with study assessments (e.g., severe infection). - History of medical conditions other than GM2 gangliosidosis/NP-C that, in the opinion of the PI; would confound scientific rigor or interpretation of results. - Presence of another inherited neurologic disease. - The dose of anti-epileptic treatment(s) was not stable and/or a new anti-epileptic treatment (drug or procedure) was prescribed during the last month before baseline. - Total bilirubin >2 x ULN (isolated bilirubin >2 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%). - Platelet count < 100 x 10^9/L. - Presence of moderate or severe renal impairment. - Prior participation in a clinical study with an investigational drug within 3 months prior to Baseline. - Patient with a positive serum pregnancy test (tested only for women of childbearing potential) at baseline. - Breast feeding ongoing at baseline or planned during the study. - ECG with an average of triplicate QTcF interval > 440 msec. - Received treatment with enantiomers of N-Acetyl-Leucine, gene therapy, stem cell transplantation, or with any other azasugars (iminosugars) compound with similar mechanism of action within 3 months before baseline (except for miglustat for which it is 1 month). - Any known allergy to azasugars or any excipients. - Evidence of suicidal ideation with intent (Type 4-5) on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening. Only in patients judged by the PI cognitively capable to understand the concept of suicide. |
Country | Name | City | State |
---|---|---|---|
Brazil | Hospital Pequeno Principe | Curitiba | |
Brazil | Hospital de Clinicas de Porto Alegre | Porto Alegre | |
Brazil | Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira | Rio De Janeiro |
Lead Sponsor | Collaborator |
---|---|
Azafaros A.G. |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety/tolerability: Incidence and severity of treatment emergent adverse events | Through study completion, up to Week 12 | ||
Primary | Assessment of pharmacokinetic (PK) parameters in plasma: Cmax | Through study completion, up to Week 12 | ||
Primary | Assessment of PK parameters in plasma: Tmax | Through study completion, up to Week 12 | ||
Primary | Assessment of PK parameters in plasma: AUC0-24h | Concentration versus time curve calculated from time 0 to 24 hours (AUC0-24h) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03759639 -
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
|
Phase 2 | |
Withdrawn |
NCT04189601 -
Complement Activation in the Lysosomal Storage Disorders
|
||
Completed |
NCT02435030 -
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C
|
N/A | |
Completed |
NCT02534844 -
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05588167 -
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C
|
||
Withdrawn |
NCT03687476 -
Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease
|
Phase 2 | |
Enrolling by invitation |
NCT05368038 -
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
|
||
Completed |
NCT01899950 -
Longitudinal Study of Cognition With Niemann-Pick Disease, Type C
|
N/A | |
Terminated |
NCT00668564 -
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
|
Phase 2 | |
Active, not recruiting |
NCT05163288 -
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
|
Phase 3 | |
Active, not recruiting |
NCT02612129 -
Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C
|
Phase 2/Phase 3 | |
Recruiting |
NCT03471143 -
Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
|
Phase 1/Phase 2 | |
Terminated |
NCT04958642 -
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease
|
Phase 2/Phase 3 | |
Terminated |
NCT03879655 -
Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
|
Phase 2/Phase 3 | |
Completed |
NCT00975689 -
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01306604 -
Biomarker for Niemann Pick Type C Disease (BioNPC)
|
||
Recruiting |
NCT00344331 -
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
|
||
Completed |
NCT03910621 -
Safety and Efficacy of Miglustat in Chinese NPC Patients
|
Phase 4 | |
Available |
NCT04316637 -
Early Access Program With Arimoclomol in US Patients With NPC
|